TickerTalks
Browse all tickers →
TickerTalks›$XTNT
XTXTNT

Xtant Medical Holdings, Inc.

$XTNT·$48M·Medical - Devices·Healthcare
$0.29-5.3%YTD-51.9%1Y-59.5%
Price updated 10h ago·X counts updated 5d ago
XTXTNT
$XTNTXtant Medical Holdings, Inc.
$0.29-5.32%2 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $XTNT on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

2X posts · last 7 days
Sep 29Oct 11

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $XTNT — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Broken storyStalledAI verdict · as of 2026-10-03

The move has stalled — likely just drifts unless something new shows up.

Xtant Medical at $0.35 after a 52% YTD drawdown — specialty-biologics with revenue decline and thin liquidity.

Xtant Medical is a specialty-biologics-and-medical-device company whose 2026 drawdown reflects both specific revenue decline and broader orthopedic-surgical-market pressure.

  • The P&L is deteriorating: Q2 revenue was down 35% YoY to $23M at a -39.8% operating margin and EPS of -$0.07, with trailing EPS prints missing Street by 250% then 33.3% — these are the kinds of misses on a specialty-medtech company whose top-line decline is accelerating.
  • The specific operational signal is substantive but small: Xtant Medical's exclusive partnership with BioHorizons expanding Access to Xtant's Allogeneic Growth Factor into the Dental Market — this is a specific product-expansion signal but on a very small base.

At 12% of its 52-week range and 30% below the 200-day with volume at 0.01x average going into Nov 10 earnings, the setup is a classic broken-story stalled microcap. A clean revenue-stabilization print plus continued BioHorizons dental-market revenue is the trigger for a reversal; another large revenue decline is the invalidation.

What to watch: Nov 10 Q3 earnings — revenue direction, BioHorizons dental-market contribution, operating margin direction, and FY27 guide. Revenue stabilization plus dental growth is the trigger; another revenue decline is the invalidation.

On the calendar: 2026-11-10 — Q3 earnings

event ahead 30dspecialty biologics broken

Read the AI verdict on $XTNT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Medical device company making bone graft substitutes and spinal implants for orthopedic and spine surgery procedures.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $XTNT.

Medical - Devices · Healthcare

Aging population demographics and AI-assisted device adoption (smart implants, continuous glucose monitors, digital health integration) are the long-cycle structural drivers. Reimbursement timing for new modalities (CMS coverage decisions) and procedure volume recovery from COVID-era deferred care shape the 2026 revenue trajectory.

What this means for $XTNT

Partial — Medical device company making bone graft substitutes and spinal implants for orthopedic and spine surgery procedures.

Industry benchmark

21-name peer basket
+12.5%YTD
+2.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-4.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-15.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-9.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-1.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-23.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
59.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 11, 2026$-0.07$-0.02-250.0%
Q1 2026May 13, 2026$-0.02$-0.01-33.3%
Q4 2025Mar 31, 2026$0.00$-0.00+108.2%
Q3 2025Nov 10, 2025$0.01$-0.01+290.5%
Next earningsTue, Nov 10·consensus EPS $-0.03

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$23.0M-35.0%57.9%-39.8%$-0.07$-7.6M
Q1 FY26$20.9M-36.5%57.3%-14.0%$-0.02$-2.3M
Q4 FY25$32.4M+2.7%54.9%-2.9%$0.00$5.0M
Q3 FY25$33.3M+19.0%66.1%7.6%$0.01$4.2M

Forward consensus

5-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$99.4M$99.2M – $99.7M-$0.03-$0.03 – -$0.022
FY27$110.2M$109.8M – $110.7M-$0.01-$0.01 – -$0.012
FY28$118.8M$115.9M – $121.6M-$0.02-$0.09 – $0.053
FY29$132.1M$130.6M – $133.3M$0.00$0.00 – $0.001
FY30$143.5M$141.9M – $144.8M$0.00$0.00 – $0.002

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.2%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-16.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-40.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 11 other (8 awards · 3 inkinds) in window

See when $XTNT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteAug 78-K — Item 5.07: Shareholder vote
AI summary

Xtant Medical Holdings held its 2026 Annual Meeting of Shareholders on August 7, 2026. All six director nominees were elected, receiving approximately 80 million votes for versus fewer than 1.1 million withheld, out of 140.3 million shares represented (quorum). Shareholders also ratified Grant Thornton LLP as the company's independent registered public accounting firm. This was a routine annual meeting with no contested elections or failed proposals.

+ 12 other (4 S-8 POSs · 2 10-Qs · 2 proxys · 1 earnings 8-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Xtant Medical Announces Exclusive Partnership with BioHorizons to Expand Access to Xtant's Allogeneic Growth Factor into the Dental Marketprnewswire.com·51d agoXtant Medical Holdings, Inc. (XTNT) Q2 2026 Earnings Call Transcriptseekingalpha.com·67d agoXtant Medical Reports Second Quarter 2026 Financial Resultsprnewswire.com·67d agoXtant Medical to Announce Second Quarter 2026 Financial Results on August 11, 2026prnewswire.com·72d agoXtant Medical to Participate in the Canaccord Genuity 46th Annual Growth Conferenceprnewswire.com·74d ago

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TMDX$MDT$QSI$BIO$ABT$PACB$BSX$BFLY
Voices on X · last 7 days

No standout posts about $XTNT on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport